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LETTER TO THE EDITOR
Management of hepatocellular carcinoma in the time
of COVID-19
To the Editor,
We have read the paper by Zhang et al.1 reporting severe
Coronavirus disease 2019 (COVID-19) in 28 cancer patients
from China. Among these patients, there were two (7%)
with hepatocellular carcinoma (HCC), who are at high risk of
poor outcomes, if infected, according to age, comorbidities,
and underlying cirrhosis. However, we should also consider
the collateral damage it brings to the systems of care on
which our patients depend, including interruption and delay
in the schedule of HCC screening, treatments, and follow-
up. Currently, Italy is facing the COVID-19 pandemic as
are other Western countries, with clinical activities being
reduced and postponed to minimize the risk of transmission
and to have all health personnel involved in facing the
emergency.
We agree that more intensive attention should be paid to
patients with cancer during the COVID-19 crisis, both for
reducing the risk of severe acute respiratory syndrome-
related coronavirus-2 (SARS-CoV-2) infection and ensuring
appropriate cancer patient management programs. In our
center, all HCC cases are managed following European As-
sociation for the Study of the Liver (EASL) guidelines and
the Barcelona Clinic Liver Cancer (BCLC) staging system
based on discussion from multidisciplinary meetings.2,3 To
tackle the COVID-19 crisis by reducing as low as possible the
risk of patients’ exposure to SARS-CoV-2 and spreading of
the infection within the hospital, we modified the man-
agement algorithm as follows:
 Telemedicine by video call has been preferred to face-to-
face visits.
 The weekly multidisciplinary meetings are conducted by
conference calls, sharing images online to reduce the risk
for health-care operators without delaying decisions.
 Indications for liver transplantation (LT) have not
changed, although management follows a recently pub-
lished algorithm.4 In summary, we have reserved LT for
patients with high risk of drop-out due to progression
of HCC. This decision has been made not only because
of the shortage of intensive care unit beds availability,
but also following the dramatic reduction in the donor
pool.
 Moreover, to reduce the risk of disease progression dur-
ing the waiting period, we encouraged locoregional
treatment (LRT) as bridge treatment to LT, whenever
possible.
 The SARS-CoV-2 test is carried out in all patients 1 day
before admission; only negative patients are admitted
to dedicated rooms in our ward (to protect them againstVolume xxx - Issue - - 2020nosocomial SARS-CoV-2 infection). To ensure safety for
both our patients and providers, protocols have been
implemented to prepare the staff and angiographic suite
before the arrival of patients, by optimizing the ventila-
tion systems and intraprocedural plus postprocedural
workflow.5
 LRTs, such as microwave thermal ablation and radiofre-
quency thermal ablation (TA), are preferred to surgical
resection to reduce both the needs of postoperative
stays in the intensive care unit and hospitalization
time, leaving surgery as a salvage option only in cases
not achieving complete radiological response or not
appropriate for LRTs.
 Palliative treatments, such as transarterial chemo(radio)
embolization (TACE, TARE), are maintained, but post-
poned in the elderly (>80 years) and in patients with
comorbidities, to minimize risk connected to hospitaliza-
tion, weighing the oncological benefit versus the risk of
exposure to SARS-CoV-2.
 The management of patients with advanced HCC treated
with systemic drugs has been modified as well. Home
blood sampling and drug delivery were implemented
together with video calls to manage common adverse
events. Intravenous anticancer therapies are dispensed
in a dedicated section of our outpatient service.
 Imaging techniques carried out for diagnosis or staging
are revised via the intranet, telemedicine, or after
courier delivery. As far as patients who receive any treat-
ment, radiological follow-up is scheduled as usual, but
postponed up to 3 months in elderly patients and in
those with comorbidities.
According to these modifications in our HCC manage-
ment, we compared our performance between 24 February
and 20 March 2020 with that in the same time frame in
2019 (Table 1). In summary, the HCC treatments for 42
patients were scheduled with a delay of 2 months in only
11 (26%) patients: two TA, four TACE, three TARE, and two
systemic therapies. TAs were carried out instead of pre-
planned surgical resection in three patients.
As the pandemic evolves, our approach to HCC man-
agement will be reviewed and our procedures updated.
However, we believe that many of these changes imple-
mented today to face this crisis will remain useful in man-
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Table 1. Management of HCC patients before and during COVID-19
emergency: a 4-week period in 2019 was compared with a 4-week
period in 2020
Management 25 February
to
22 March
2019
24 February
to
20 March
2020
Outpatient visits, n 117 77a
Cases discussed in multidisciplinary
meetings, n
46 42
Liver transplants for HCC, n 3 1
Surgical resections, n 3 2
MWTA and RFA, n 4 7
TACE, n 9 4
TARE, n d 1
Total number of patients admitted to the
ward
58 48
MWTA, microwave thermal ablation; RFA, radiofrequency ablation; TACE, trans-
arterial chemoembolization; TARE, transarterial radioembolization.
a Week 1: 35 visits; week 2: 23 visits; week 3: 17 visits; and week 4: 2 visits.
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